InsidersTradesSigma
Follow the Pyxis Oncology, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Pyxis Oncology, Inc. has recorded 59 insider filings. Market capitalisation: €149.5m. The latest transaction was disclosed on 30 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Wadhane Jitendra. Every trade is openly available.
59
Insider Decl.
n/a
Thresholds
€10m
12 ops.
Buy Volume
€5m
4 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Pyxis Oncology, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$6.75.
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,455 of 29,062 companies
27.4
score / 100
Value8
Quality46
FCF yld-24%
Earn yld-30%
EV/EBITDA·
ROE-179%
Gross mgn83%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 30 June 2026
Declarations59 total
35,000 shares@ US$3.05810.063% mcap100.0% of flowCommonSEC144:0001959173-26-004977
109,461 shares0Common StockSEC:0001193125-26-124380:0
1,400 shares@ US$0.97270.0008% mcap50.0% of flowCommon StockSEC:0000905148-26-001434:0
5,450 shares@ US$2.009.5% of flowCommon StockSEC:0000950170-24-131606:0
Canonical exit: 24 Feb 2025 (T+90)
6,000 shares0Common StockSEC:0000950170-24-070833:0
38,741 shares0Common StockSEC:0000950170-24-038099:0
38,741 shares0Common StockSEC:0000950170-24-038102:0
35,219 shares0Common StockSEC:0000950170-24-038105:0
131,484 shares0Common StockSEC:0000950170-24-038097:0
35,219 shares0Common StockSEC:0000950170-24-038103:0
328,710 shares0Common StockSEC:0000950170-24-038108:0
35,219 shares0Common StockSEC:0000950170-24-038104:0
36,949 shares@ US$1.4042.7% of flowCommon StockSEC:0001209191-23-056969:0
40,000 shares0Common StockSEC:0001209191-23-055744:0
8,000 shares@ US$1.8727.0% of flowCommon StockSEC:0001209191-23-050734:0
Canonical exit: 27 Dec 2023 (T+90)
6,426 shares@ US$1.846821.5% of flowCommon StockSEC:0001209191-23-050685:0
Canonical exit: 26 Dec 2023 (T+90)
2,500 shares@ US$1.8726.4% of flowCommon StockSEC:0001209191-23-050686:0
Canonical exit: 26 Dec 2023 (T+90)
5,000 shares@ US$1.7749.5% of flowCommon StockSEC:0001209191-23-050495:0
Canonical exit: 24 Dec 2023 (T+90)
12,000 shares@ US$1.670336.0% of flowCommon StockSEC:0001209191-23-050492:0
Canonical exit: 24 Dec 2023 (T+90)
5,000 shares@ US$1.73915.5% of flowCommon StockSEC:0001209191-23-050432:0
Canonical exit: 21 Dec 2023 (T+90)
2,500 shares@ US$1.739724.2% of flowCommon StockSEC:0001209191-23-050433:0
Canonical exit: 21 Dec 2023 (T+90)
100 shares@ US$2.250.5% of flowCommon StockSEC:0001209191-23-049826:0
20,000 shares@ US$2.270799.5% of flowCommon StockSEC:0001209191-23-049366:0
187,793 shares0Common StockSEC:0001209191-23-048819:0
93,896 shares0Common StockSEC:0001209191-23-048816:0
25 of 59 declarations
关于 Pyxis Oncology, Inc.
Pyxis Oncology, Inc.（股票代码：PYXS）是一家在美国纳斯达克上市的生物技术公司，属于医疗保健和制药综合体。该公司成立于2018年6月，并于2019年7月开始运营。其总部位于美国领先的生物技术集群波士顿，马萨诸塞州。自成立以来，Pyxis一直围绕肿瘤学理论构建，专注于肿瘤微环境，旨在创造能够直接攻击癌细胞同时解决免疫抑制和免疫逃逸的疗法。（[ir.pyxisoncology.com](https://ir.pyxisoncology.com/static-files/be1b7460-c18f-41f5-b85d-de9ec789acdd?utm_source=openai)） Pyxis Oncology 的业务模式以临床阶段管线为中心，重点是抗体-药物偶联物（ADCs）和精选的免疫肿瘤学项目。公司的核心方法是通过靶向生物制剂将高效载荷直接递送至肿瘤组织，这可能比传统化疗提供更具选择性的治疗方案。其领先且最受关注的资产是 PYX-201，一种临床阶段的 ADC，并辅以其他项目和平台能力。通过2023年收购 Apexigen，管线得到了实质性扩展，增加了抗体生成权并增强了公司的开发工具包。（[ir.pyxisoncology.com](https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-advances-pyx-106-and-pyx-201-clinical-programs?utm_source=openai)） 在竞争方面，Pyxis 占据了一个竞争激烈但具有战略重要性的利基市场：临床阶段肿瘤生物技术。它与大型制药公司和专业的 ADC/免疫肿瘤学公司竞争，因此其差异化取决于科学新颖性、临床执行和明智的合作。该公司强调与默克公司合作进行一项临床研究，将 PYX-201 与 KEYTRUDA 结合使用，这是该项目战略相关性的一个重要验证点。Pyxis 正在针对难以治疗的实体瘤，包括头颈癌、乳腺癌和某些肉瘤，这些领域存在高度未满足的医疗需求，成功的临床数据可能具有重要的商业意义。（[ir.pyxisoncology.com](https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-announces-favorable-preliminary-pyx-201-clinical/?utm_source=openai)） 最近的发展仍集中在临床进展和资本纪律上。2026年3月，Pyxis 公布了2025年全年业绩，并表示现金和现金等价物预计将为运营提供资金至2026年第四季度。该公司还表示，预计将在2026年披露额外的临床前和临床数据，同时管理层变动支持了下一阶段的执行。对于投资者而言，PYXS 最好被视为一家高风险、高回报的肿瘤生物技术公司：股权案例由管线里程碑驱动，但投资概况仍然高度依赖于临床结果、合作和未来的融资需求。（[ir.pyxisoncology.com](https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-provides-business-update-and-reports-fourth?utm_source=openai)）
